Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin act⦠read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
$38.67
Price-0.13%
-$0.05
$4.627b
Mid
-
Premium
Premium
-14838.8%
EBITDA Margin-16244.7%
Net Profit Margin-15299.8%
Free Cash Flow Margin$19.218m
-50.2%
1y CAGR-36.0%
3y CAGR-20.4%
5y CAGR-$615.259m
-0.8%
1y CAGR-32.5%
3y CAGR-36.3%
5y CAGR-$5.29
+0.9%
1y CAGR-21.0%
3y CAGR-21.7%
5y CAGR-$266.413m
$1.264b
Assets$1.530b
Liabilities$791.055m
Debt62.6%
-1.6x
Debt to EBITDA-$409.324m
-1.2%
1y CAGR-32.5%
3y CAGR-2268.1%
5y CAGR